- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 212 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 20.08. | Marvel Biosciences Corp: Marvel Biosciences expands financing to Quebec | 2 | Stockwatch | ||
| 19.08. | Marvel Biosciences Corp.: Marvel Biosciences Expands Private Placement to Quebec | 454 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private... ► Artikel lesen | |
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.08. | Marvel Biosciences Corp: Marvel Biosciences talks MB-204 preclinical data | 1 | Stockwatch | ||
| 05.08. | Marvel Biosciences Corp.: Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X | 166 | GlobeNewswire (Europe) | CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 17.07. | Marvel Biosciences Corp: Marvel Biosciences arranges minimum $1.5M placement | 1 | Stockwatch | ||
| 16.07. | Marvel Biosciences Corp.: Marvel Biosciences Announces Private Placement for up to $3.0 Million | 547 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered... ► Artikel lesen | |
| 26.06. | Marvel Biosciences Corp.: New Autism Research to be Presented at European Purine Scientific Meeting | 1 | GlobeNewswire (USA) | ||
| 08.06. | Marvel Biosciences Corp: Marvel gains Australian patent allowance for MB-204 | 1 | Stockwatch | ||
| 08.06. | Marvel Biosciences Corp.: Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 | 212 | GlobeNewswire (Europe) | CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 20.05. | Marvel Biosciences Corp: Marvel Biosciences grants 50,001 DSUs to 3 directors | 1 | Stockwatch | ||
| 20.05. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 259 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 30.04. | Marvel Biosciences Corp: Marvel Biosciences $500,000 debenture private placement | 3 | Stockwatch | ||
| 23.04. | Marvel Biosciences Corp.: Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit | 1 | GlobeNewswire (USA) | ||
| 17.04. | Marvel Biosciences Corp: Marvel Biosciences closes $500,000 debenture offering | 2 | Stockwatch | ||
| 17.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Convertible Debenture Offering | 788 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced... ► Artikel lesen | |
| 16.04. | Marvel Biosciences Corp: Marvel Biosciences develops MB-204 liquid formulations | 3 | Stockwatch | ||
| 16.04. | Marvel Biosciences advancing autism drug for children | 1 | The Market Online Canada | ||
| 16.04. | Marvel Biosciences Corp.: Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders | 199 | GlobeNewswire (Europe) | CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 14.04. | Marvel Biosciences Corp: Marvel Biosciences amends debenture conversion price | 1 | Stockwatch |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALUMIS | 9,470 | -56,58 % | Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) | - LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,680 | -0,91 % | $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| QIAGEN | 37,355 | +0,32 % | QIAGEN profitiert von neuen Spekulationen: QIAGEN Aktie zieht wieder an Übernahmegespräche sorgen für frischen Rückenwind | Die QIAGEN Aktie erholt sich nach zwei schwächeren Handelstagen wieder. Neue Spekulationen über mögliche Übernahmegespräche sorgen am Markt für Kaufinteresse.Übernahmefantasie treibt den Kurs Die QIAGEN... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 41,250 | +4,75 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| BIOAFFINITY TECHNOLOGIES | 6,580 | +35,11 % | bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced... ► Artikel lesen | |
| ERASCA | 16,770 | -6,08 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,160 | +3,96 % | Cantor Fitzgerald reiterates Summit Therapeutics stock rating | ||
| MODERNA | 133,08 | +10,11 % | Milliardenmarkt Krebs: Moderna und Merck läuten die nächste Biotech-Ära ein | Ein Durchbruch in der Krebsforschung sorgt für Euphorie an der Börse. Moderna und Merck feiern einen Studienerfolg. Jetzt hoffen Anleger auf die nächste große Biotech-Rallye und neue Milliardenmärkte.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 353,24 | +0,84 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 25,570 | -0,39 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval - - Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 135,07 | +0,01 % | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,420 | +1,30 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| IMMUNOVANT | 39,920 | -2,20 % | Cantor Fitzgerald reiterates Immunovant stock Overweight rating | ||
| 4D MOLECULAR THERAPEUTICS | 14,350 | +1,70 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population | After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 33,850 | +0,30 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
MARVEL BIOSCIENCES CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.